Backgrounds: New-generation bioresorbable polymer-everolimus eluting stents (BP-
| PCI procedure
Patients who had undergone emergent PCI in this study presented to the emergency room with a suspected acute coronary syndrome.
Aspirin (200 mg) was administered orally in the emergency room, followed by a daily maintenance per oral dose of 100 mg thereafter. In addition, the patients were also administered clopidogrel or prasugrel, at a loading dose of 300 mg or 20 mg, respectively, with a daily maintenance per oral dose of 75 mg for clopidogrel and 3.75 mg for prasugrel thereafter.
In the other hand, patients who had undergone elective PCI were prescribed oral dose of aspirin (100 mg) with combined another antiplatelet drug (75 mg for clopidogrel or 3.75 mg for prasugrel) at least for 3 days before PCI. Thereafter, dual anti-platelet therapy (DAPT) was continued for at least 1 year after PCI. Furthermore, unfractionated heparin was administered intravenously to achieve an activated clotting time of 200-250 s during PCI. The stenting procedure, routinely utilized at each hospital, involved the use of a 6-French arterial sheath and a transbrachial or transfemoral artery approach was utilized in patients who required HD, while a radial artery approach was utilized in patients who did not require HD. Angiography was performed using a 6 F guiding catheter to identify the site of the culprit lesion. A 0.014-inch coronary guidewire was passed through the lesion. Thereafter, the pre-dilatation, stent type selection (BP-EES, PtCr-EES, and CoCr-EES) and postdilatation procedures were performed at the discretion of the surgeon, including the use of rotablator atherectomy and imaging, such as intravascular ultrasound (IVUS), with the objective of achieving optimal results. Calcified lesions were defined as fixed radiopaque densities seen in the area of the stenosis, as shown in Figure 1 , and graded as follows:
mild, difficult to detect; moderate, easily identifiable; and heavy when they were of the same density as the spine. 
| Quantitative coronary angiography (QCA)
Contrast-filled guide catheters were used as the reference standard in QCA (QAngio XA, Medis, Japan). Late lumen loss was defined as the difference between the minimal stent diameter (MSD) of the target vessel immediately after PCI and the lumen diameter at the 12-month follow-up angiography. The length of the culprit lesion, the diameter of the reference vessel, the MSD, and the percent diameter stenosis (% DS) were also measured. Chronic total occlusion was defined as a 100% DS on angiography. Other identified coronary lesions were classified according to the American Heart Association/American College of Cardiology (AHA/ACC) criteria. 
| Clinical follow-up
Target lesion revascularization (TLR), stent thrombosis (ST), and major adverse cardiac event (MACE) were recorded. MACE was defined as cardiovascular death, myocardial infarction, repeat PCI, or coronary artery bypass graft surgery.
| Statistical analysis
All statistical analyses were performed using IBM SPSS (version 22; IBM Japan corporation, Tokyo, Japan). Continuous variables were expressed as mean ± standard deviation and were compared with the Student SATO ET AL.
| 171 unpaired t-test. Categorical variables were expressed as counts and percentages, and the chi-square test was used for comparison.
Differences among the BP-EES, PtCr-EES, and CoCr-EES groups were evaluated using an analysis of variance (ANOVA) for parametric data and a Kruskal-Wallis one-way ANOVA on ranks for nonparametric data, followed by multiple comparisons using Dunn's method. A two-sided Pvalue of <0.05 was considered statistically significant for all analyses.
| RESULTS
Relevant baseline patient and angiography characteristics are summarized in Tables 1 and 2 . The study group was predominantly male (76%), with a mean age of 74 years. 41% of enrolled patients was in need for HD. 56% of enrolled patients was stable angina pectoris. There were no significant differences among the three stent groups with regard to patient characteristics, including duration of HD and presence of diabetes mellitus, and characteristics of the lesion, including QCA parameter, the severity of calcification and ACC/AHA classification before PCI procedure, and coronary intervention procedure, such as the diameter and length of the implanted stent and the use of a rotablator. However, the frequency of IVUS use was significantly higher in the BP-EES group than the CoCr-EES and PtCr-EES groups.
FIGURE 1
The calcification grade within the segment of the culprit lesion on quantitative coronary angiography. Lesion calcification was defined as fixed radiopaque densities seen in the area of the stenosis, and it was graded as minimal when they were difficult to detect, moderate when they were easy to detect, and heavy when were of spine density. Mild to severe calcification grade were shown in Figure  ( there were also not significant differences among BP-EES, CoCr-EES, and PtCr-EES with regard to %DS values (10.2 ± 10.5 vs 7.8 ± 6.7 vs 9.5 ± 10.7%; P = 0.42) (Table 3) .
However, at follow up, the MSD in the BP-EES group was significantly lower than the MSD in the PtCr-EES and the CoCr-EES (2.16 ± 0.95 vs 2.51 ± 0.93 vs 2.55 ± 0.64 mm; P = 0.04). Furthermore, the late lumen loss at follow-up was also significantly greater in the BP-EES than in the PtCr-EES and the CoCr-EES (0.51 ± 0.64 vs 0.20 ± 0.61 vs 0.25 ± 0.70 mm; P = 0.03) ( Table 3 ).
The overall rate of TLR and MACE was 14.6% and 30.8%, respectively, with no observation of ST. At follow-up, there were no significant differences in the rate of MACE among the three stent groups, but with a tendency to higher TLR in the BP-EES (22.7%) group than in the PtCr-EES (8.8%) and the CoCr-EES (9.6%) groups (P = 0.07; Table 4 ). 
| DISCUSSION
The main findings of our study were a higher TLR rate in the BP-EES group, than in the PtCr-EES and the CoCr-EES groups, but with a higher late lumen loss in the BP-EES group compared to the other two stent groups. To the best of our knowledge, this is the first study to have compared the usefulness of three commonly used stents (BP-EES, PtCr-EES, and CoCr-EES) in patients with end-stage CKD including HD.
PCI has been widely performed in HD patients with coronary artery disease. 1,2 However, these patients frequently have complex lesions, resulting in a higher rate of restenosis that expected after PCI. 9 In addition, several studies have identified dialysis as the strongest predictor of adverse outcomes after PCI. 10, 11 The increased risk of adverse outcomes among patients with CKD, particularly those on HD, might be associated with the severity of calcified lesions, 12 enhanced platelet activation, 13 and differences in the physiological measurement of fractional flow reserve. 14 Coronary in-stent restenosis among patients with CKD might also result from neointimal hyperplasia, a very complex process that is influenced by several pathophysiological mechanisms, including vascular inflammation, an increase of calcification promoters and the activation of the renin-angiotensin system, resulting in an enhanced production of reactive oxygen species. [15] [16] [17] Differences in clinical outcomes between BP-EES and PtCr-EES, as well as between BP-EES and CoCr-EES, have previously been reported, 18, 19 with comparable clinical outcomes having been reported for BP-EES and CoCr-EES, even for real-world complex patients. 6 However, these protocols excluded patients on HD. Therefore, the impact of the end-stage CKD and HD on the clinical outcomes after BP-EES implantation remained unknown. Even for CoCr-EES, only on previous study included patients on HD, reporting a late lumen loss of 0.26 mm, based on 50 patients on HD, 5 which is comparable to the findings in our study.
Irrespective of stent design, comparable clinical outcomes have been reported for CoCr-EES and PtCr-EES which use the same polymer and drug, but have a different stent design. 20 Similarly, in our study, no effect of stent design or patient and lesion characteristics were identified on the %DS and MSD.
Several mechanisms relating TLR to stent type have been described, 21 with the thickness of the strut likely influencing the rate of restenosis. 22 The strut thickness is thinner for BP-EES (74 µm in a stent with less than and equal to 2.5 mm in diameter or 79 µm in a stent with a diameter >2.5 mm) than for PtCr-EES and CoCr-EES designs (81 µm). Based on strut thickness alone, better clinical outcomes would be expected for the BP-EES design than for both PtCr-EES and CoCr-EES. Our findings indicate that factors other than strut thickness are likely to influence clinical outcomes after stent implantation. The drug used and its method of release, as well as the polymer used for each DES could influence outcomes. However, in our study, all three stent designs used the same drug and the same method of release. Therefore, we suggest that drug-related factors may not exert a significant
| Limitations
The limitations of this study are as follows. First, we used a previous report on the effect of CoCr-EES on late-loss in patients who required HD (approximately, 0.37 mm) to estimate a sample size of 47 subjects per group. 1 Sample size estimates were based on the following: standard deviation, 0.63; α-level, 0.05; and power, 80%. However, the number of study patients might be still small. Furthermore, this was retrospective and nonrandomized study. Therefore, no definite conclusion can be drawn out of the present study. Second, the rate of the use of rotational atherectomy and IVUS was very low in the present study, with the use of these devises likely to influence results.
Third, in the present study, the frequency of IVUS was significantly higher in the BP-EES group than in the PtCr-EES and CoCr-EES groups. In addition, the severity of calcification was not evaluated using IVUS in all cases, as mentioned above. We should have evaluated the calcification types, such as superficial calcification, thickness and arc of calcification and calcified nodule, using optical coherence tomography (OCT) or IVUS. In fact, a previous study has reported the beneficial effect regarding the use of rotational atherectomy and coronary imaging devise such as OCT for severe calcified lesion, 30 warranting future studies involving larger populations and longer longitudinal follow-up periods.
| CONCLUSION
BP-EES might increase the risk for in-stent restenosis in patients with end-stage CKD or the need for HD.
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